Which asthma biologic is the most popular of them all? by Angus Liu Thursday, November 21, 2019 In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.
Novartis' Xolair eyes sinusitis to backstop blockbuster sales by Kyle Blankenship Tuesday, June 4, 2019 Facing stiff competition in asthma, Novartis’ Xolair can use all the help it can get to keep its blockbuster status. Could sinusitis be the cure?
AZ's Fasenra benefits hold up for 2 years: analysis by Eric Sagonowsky Monday, May 20, 2019 AstraZeneca has released data showing its med's effects can last up to two years in severe asthma.
4. Novartis by Angus Liu To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Novartis, aiming to keep Xolair sales, pushes successor to ph3 by Carly Helfand Thursday, December 6, 2018 With blockbuster Xolair aging, Novartis is looking to usher in a successor to protect its sales. And it got one step closer this week.
Sanofi's Dupixent set for $2.5B in peak asthma sales: analyst by Eric Sagonowsky Monday, October 22, 2018 Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.
Roche, Novartis to debut new version of aging blockbuster Xolair by Carly Helfand Wednesday, October 3, 2018 Roche and Novartis want to keep aging Xolair competitive for as long as possible, and they recently took a big step forward in doing that.
5 antibody drugs for asthma show benefits but cost too much—ICER by Angus Liu Wednesday, September 26, 2018 Xolair, Nucala, Cinqair, Fasenra and Dupixent will need to take a 50% to 68% discount off the list price to achieve cost-effectiveness, says ICER.
AZ stands up to respiratory rivals with tezepelumab breakthrough by Carly Helfand Friday, September 7, 2018 It hasn’t been an easy summer for AstraZeneca in the respiratory department, but the British drugmaker has finally come up with a win.
Xolair, pressed in asthma, wins food allergy 'breakthrough' by Carly Helfand Monday, August 13, 2018 Roche’s Xolair has seen competitors encroach on its territory over the last few years. But now, it’s ready to carve out a new niche of its own.
